News

Filter

Current filters:

FycompaResearch

New data provides additional evidence for use of Eisai's Fycompa in partial-onset epilepsy

26-06-2013

Additional data on the safety, efficacy and impact on quality of life (QOL) of Japanese drug major Eisai's…

EisaiFycompaNeurologicalPharmaceuticalResearch

Eisai's Fycompa shows clear therapeutic benefit in hard-to-treat epilepsy

10-05-2013

Japanese drug major Eisai's (TYO: 4523) antiepileptic drug (AED) Fycompa (perampanel), shows a clear…

EisaiFycompaNeurologicalPharmaceuticalResearch

Eisai's Fycompa gets first EU launch, in UK; links with Sabine Vaccine Inst

13-09-2012

Japanese drug major Eisai (TYO: 4523) has announced the first European launch today of Fycompa (perampanel),…

EisaiFycompaMarkets & MarketingNeurologicalPharmaceuticalResearchTropical diseasesVaccines

Positive final pivotal Ph III results for Eisai's Fycompa

21-08-2012

Results from the final pivotal Phase III study and long term Phase III extension study of Japanese drug…

EisaiFycompaNeurologicalPharmaceuticalResearch

Eisai's Fycompa improves seizure control, pivotal Ph III study shows

27-07-2012

Japanese drug major Eisai (TYO: 4523) announced results from a pivotal Phase III clinical trial (Study…

EisaiFycompaNeurologicalperampanelPharmaceuticalResearch

Back to top